Add-On Therapy for Resistant Hypertension
In resistant hypertension, chlorthalidone added to an ARB is not consistently the most effective add-on strategy. A mineralocorticoid receptor antagonist provides larger blood pressure reductions in randomized evidence for resistant hypertension. [1][2]
Medication Selection Algorithm
For resistant hypertension with confirmed uncontrolled blood pressure despite an ARB (or ACE inhibitor) plus a calcium channel blocker plus a diuretic, add-on selection is driven by evidence for competing fourth-line agents and by kidney function. [1][3]
- Mineralocorticoid receptor antagonist (preferred fourth-line agent): spironolactone or eplerenone. [1][3]
- If mineralocorticoid receptor antagonist cannot be used and kidney function is poor (eGFR <30 mL/min/1.73 m²), thiazide-like diuretics such as chlorthalidone can be used. [3]
- If kidney function is preserved (eGFR >30 mL/min/1.73 m²), spironolactone is preferred over chlorthalidone as the fourth drug in resistant hypertension. [1][3]
Key Evidence Supporting This Recommendation
PATHWAY-2 tested fourth-drug add-on therapy in resistant hypertension already treated with an ACE inhibitor or ARB, a calcium channel blocker, and a diuretic. [1]
- Home systolic blood pressure reduction was larger with spironolactone (−12.8 mm Hg) than with placebo (−8.70 mm Hg), doxazosin (−4.03 mm Hg), or bisoprolol (−4.48 mm Hg). [1]
This evidence supports greater effectiveness from mineralocorticoid receptor blockade than from alternative add-on strategies in the resistant hypertension population studied. [1]
Monotherapy vs Combination Therapy
Resistant hypertension management is based on multi-drug therapy with complementary mechanisms rather than escalation within a single diuretic mechanism. [1][3]
- When an ARB is already part of the regimen, adding chlorthalidone may improve blood pressure control, but randomized resistant hypertension evidence indicates that adding spironolactone produces a larger incremental effect as the fourth drug. [1][3]
Important Clarifications and Nuances
Chlorthalidone is a thiazide-like diuretic. [3]
- In resistant hypertension, evidence supporting spironolactone as the most effective fourth add-on indicates that chlorthalidone is not the superior add-on strategy when mineralocorticoid receptor antagonism is feasible. [1][3]
Initiation Thresholds and Indications
Resistant hypertension is defined as uncontrolled clinic blood pressure despite maximally tolerated doses of an appropriate three-drug regimen that includes a diuretic, with confirmation of true resistance and exclusion of pseudo-resistance. [3]
Common Pitfalls to Avoid
Electrolyte and renal adverse effects can limit chlorthalidone dose escalation, particularly in older adults. [4]
- In a pragmatic trial of adults aged 65 years or older who were receiving hydrochlorothiazide, switching to chlorthalidone increased hypokalemia incidence (6.0% vs a lower rate with hydrochlorothiazide). [4]
- This increase in hypokalemia can constrain tolerability and thus reduce achievable blood pressure lowering from diuretic intensification. [4]
Target Blood Pressure
Resistant hypertension treatment aims for controlled blood pressure consistent with major guideline targets used for the overall hypertension population, after confirmation of true resistant hypertension and optimization of core regimen components. [3]
Bottom-Line Clinical Reason
Chlorthalidone is not a better add-on to losartan because resistant hypertension studies show larger incremental blood pressure reductions from mineralocorticoid receptor antagonism than from other add-on options, and chlorthalidone intensification is constrained by higher rates of hypokalemia in older adults. [1][4]